COSENTYX
As listed in the register: COSENTYX
150 mg · solution
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Secukinumab
- Made by
- Novartis Pharmaceuticals Canada Inc
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (COSENTYX). It describes the substance, not this exact product.
Secukinumab is a human IgG1 monoclonal antibody that selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor.
IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-08-25
Safety of the active substance
From the US prescribing label for the same active substance (COSENTYX). It describes the substance, not this exact product.
- COSENTYX is contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or to any of the excipients in COSENTYX.
- Cases of anaphylaxis and angioedema have been reported during treatment with COSENTYX [see Warnings and Precautions (5.2)].
- Serious hypersensitivity to secukinumab or any excipients in COSENTYX.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Novartis Pharmaceuticals Canada Inc |
|---|---|
| Active substance | Secukinumab |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 150 mg |
| Form | solution |
| Classification | L04AC10 · Cancer treatments and immune-system medicines |
| Route | subcutaneous |
| Dispensing (as stated by the register) | PRESCRIPTION · SCHEDULE D |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02547724 |
| DPD drug code | 103665 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
6 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- solution5 products
- 75 mg
150 mg2
150 mg · 2 companies
- Novartis Pharmaceuticals Canada Inc · this page
- Novartis Pharmaceuticals Canada Inc
300 mg2
300 mg · 2 companies
- powder for solution1 products
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.